Weight loss drug launched in India, will reduce sagging fat, weight will reduce up to 21 kg, know the price and where to get it
In India, around 101 million people suffer from diabetes. More than half of these patients do not have their blood sugar under control. At the same time, obesity is affecting around 100 million people. This medicine can help deal with obesity and diabetes simultaneously.
American pharmaceutical company Eli Lilly has launched its diabetes and weight loss drug Mounjaro in India. This drug has come after getting approval from India's drug regulator. The company gave this information on Thursday. The price of 5 MG vial of Mounjaro will be Rs 4,375 and the price of 2.5 MG vial will be Rs 3,500. This special price has been kept in India so that more and more people can access this modern treatment.
The demand for Lilly's diabetes and weight loss drugs is increasing worldwide. The launch of this drug in India is a big opportunity. India is the most populous country in the world and cases of obesity and diabetes are increasing here. The company claims that this drug can prove to be a new and effective way to improve metabolic health and reduce weight.
Diabetes and obesity are serious problems in India
Lilly India said that obesity and type 2 diabetes are becoming a major health problem in India. Around 10.1 crore people in India suffer from diabetes and obesity is a major cause of diabetes. This means that it is a serious concern that needs to be addressed.
The drug is being used a lot in America and Europe
Monjaro's chemical name is Tirzepatide, and it is currently being sold under this name in the UK and Europe for both diabetes and weight loss. In the US, it is available for obesity under the name Zepbound. Experts believe that the market for obesity-reducing drugs is going to be very large in the coming years. They estimate that by 2030, the sale of these drugs could reach $150 billion.
How does this medicine work?
This medicine is taken once a week and can cost between ₹14,000 and ₹17,500 per month depending on the dosage prescribed by the doctor. It is the first medicine for obesity and type 2 diabetes that activates the GIP and GLP-1 hormone receptors. This medicine can provide a new and effective treatment that can improve the metabolic health of patients. It helps in increasing insulin production in the body, reducing glucagon levels, improving insulin sensitivity and controlling appetite. It reduces the amount of fat in the body and regulates lipid utilization.
How much weight can I lose with Monjaro?
According to a clinical trial published in the New England Journal of Medicine ( ref ), people taking Monjaro along with diet and exercise lost an average of 21.8 kg (at the 15 mg dose) and 15.4 kg (at the 5 mg dose) over 72 weeks.
Increasing demand for GLP-1 drugs
The demand for GLP-1 class drugs for the treatment of diabetes and obesity is growing rapidly. This market is now worth hundreds of billions of dollars. The patent of Semaglutide, a major drug in this category, is expiring in March 2025. After this, many Indian companies are preparing to launch generic versions of this drug.
Disclaimer: This article is for general information only. It cannot in any way be a substitute for any medicine or treatment. Always contact your doctor for more information. NC does not take responsibility for its truth, accuracy and effectiveness.
PC:NBT
